MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Meropenem is primarily metabolized by hydrolysis of the beta-lactam ring via renal dehydropeptidase-1 (DHP-1) located in the kidney, producing an inactive metabolite. It is not significantly metabolized by hepatic CYP450 enzymes. |
| Excretion | Renal: ~70% unchanged via glomerular filtration and tubular secretion; hepatic metabolism: ~20% via hydrolysis of beta-lactam ring; fecal: <2%. |
| Half-life | 1.0–1.5 hours in healthy adults; prolonged to 4–6 hours in moderate renal impairment (CrCl 30–50 mL/min) and 8–12 hours in severe renal impairment (CrCl <10 mL/min). |
| Protein binding | ~2% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 0.23–0.35 L/kg, approximating extracellular fluid volume; indicates limited tissue penetration except in inflamed tissues. |
| Bioavailability | IV: 100% (only route); no oral bioavailability. |
| Onset of Action | IV: Immediate therapeutic concentrations achieved in plasma within 30 minutes of infusion start; clinical effect typically observed within 1–2 hours. |
| Duration of Action | Administration every 8 hours maintains plasma levels above MIC for most susceptible pathogens for approximately 60% of the dosing interval; prolonged in renal impairment. |
| Molecular Weight | 383.46 |
1 g IV every 8 hours infused over 15-30 minutes; dose range 0.5-2 g every 8 hours depending on infection severity
| Dosage form | POWDER |
| Renal impairment | CrCl 26-50 mL/min: 1 g every 12 hours; CrCl 10-25 mL/min: 0.5 g every 12 hours; CrCl <10 mL/min: 0.5 g every 24 hours |
| Liver impairment | No adjustment required for hepatic impairment; pharmacokinetics unaffected by Child-Pugh class |
| Pediatric use | Infants ≥3 months and children: 20-40 mg/kg IV every 8 hours (max 2 g/dose); higher doses up to 60 mg/kg every 8 hours for meningitis |
| Geriatric use | Dose based on renal function (CrCl); no age-specific adjustments beyond renal considerations |
| 1st trimester | Meropenem crosses the placenta. Human data are limited; animal studies show no teratogenicity. Use only if clearly needed. |
| 2nd trimester | Same as t1. No increased risk of malformations reported. |
| 3rd trimester | Use near term may alter neonatal gut flora; theoretical risk of kernicterus in neonates (meropenem displaces bilirubin from albumin). Consider risks vs benefits. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Meropenem crosses the placenta in humans. Fetal plasma concentrations reach approximately 50% of maternal levels. |
| Breastfeeding | Meropenem is excreted into breast milk in low concentrations. It is considered compatible with breastfeeding by the American Academy of Pediatrics. However, potential for alteration of infant gut flora and allergic sensitization. Monitor infant for diarrhea or rash. |
| Lactation Rating | L2 (Limited data - probably compatible) |
| Teratogenic Risk | Meropenem is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal harm, but no adequate and well-controlled studies exist in pregnant women. First trimester: No increased risk of major malformations reported in human data. Second and third trimesters: Use only if clearly needed; no known fetal toxicity at standard doses. However, caution is advised due to potential alteration of gut flora and risk of neonatal infection if used near delivery. |
| Fetal Monitoring | Monitor renal function (serum creatinine, BUN) and complete blood count during prolonged therapy. Assess for signs of hypersensitivity or superinfection. In pregnancy, fetal monitoring as per routine obstetrical care; no specific fetal monitoring required. |
| Fertility Effects | No evidence of impaired fertility in animal studies. No human data on fertility effects are available. |
■ FDA Black Box Warning
No FDA black box warning for meropenem; however, carbapenems may cause serious hypersensitivity reactions and should be used with caution in patients with history of beta-lactam allergy.
| Common Effects | Rash Headache Vomiting Nausea Itching Diarrhea Injection site inflammation Anemia low number of red blood cells Sepsis Constipation Apnea absence of breathing Shock |
| Serious Effects |
Hypersensitivity to meropenem or any carbapenemHypersensitivity to any beta-lactam antibiotic (severe reactions)Use of probenecid (contraindicated by manufacturer due to increased meropenem exposure)
| Precautions | Hypersensitivity reactions: Serious and occasionally fatal anaphylactic reactions, especially in patients with history of penicillin, cephalosporin, or other beta-lactam allergy., Seizures: May cause CNS adverse effects including seizures, especially in patients with renal impairment, CNS disorders, or those receiving high doses., Clostridioides difficile-associated diarrhea (CDAD): May range from mild diarrhea to fatal colitis; evaluate if diarrhea occurs., Renal impairment: Dose adjustment required; may increase risk of seizures due to accumulation., Bleeding: Reports of coagulation abnormalities, including prolonged prothrombin time and bleeding, particularly in malnourished or renal failure patients. |
| Food/Dietary | No known food interactions with meropenem. Sodium chloride content should be considered in patients on sodium-restricted diets. |
| Clinical Pearls | Meropenem is a broad-spectrum carbapenem active against Gram-positive, Gram-negative, and anaerobic bacteria. In the Duplex Container formulation, meropenem is premixed with sodium chloride for IV administration; ensure the container is intact and the solution is clear before use. Dose adjustment required in renal impairment (CrCl <50 mL/min). Prolonged infusion (e.g., over 3 hours) may optimize pharmacokinetic/pharmacodynamic targets for resistant organisms. Contraindicated in patients with hypersensitivity to carbapenems or history of anaphylaxis to beta-lactams. |
| Patient Advice | This medication is given intravenously, usually every 8 hours, and must be administered by a healthcare professional. · Inform your doctor of any kidney problems, as the dose may need to be adjusted. · Report any signs of allergic reaction, such as rash, itching, swelling, or difficulty breathing, immediately. · Notify your healthcare provider if you have seizures or epilepsy, as meropenem may lower the seizure threshold. · Complete the full course of treatment even if you feel better. |
Loading safety data…